Omega Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference
Omega Therapeutics (Nasdaq: OMGA) will be featured in a fireside chat at the 2022 Wedbush PacGrow Healthcare Conference on August 10, 2022, at 8 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Omega Therapeutics (Nasdaq: OMGA) will be featured in a fireside chat at the 2022 Wedbush PacGrow Healthcare Conference on August 10, 2022, at 8 a.m. ET. Chief Scientific Officer Thomas McCauley will represent the company, which leads in mRNA therapeutics as programmable epigenetic medicines through its OMEGA Epigenomic Programming™ platform. A live webcast will be accessible via their website, with an archived replay available for 90 days.
Details
News Market Reaction – OMGA
The recorded move for OMGA in the trading session of this news was +0.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Aug. 3, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced that Thomas McCauley, Chief Scientific Officer, will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Conference on August 10, 2022, at 8 a.m. ET.
A live webcast of the fireside chat will be available on the Investors & Media section of the Company's website at www.omegatherapeutics.com. An archived replay of the fireside chat will be available on the same website for approximately 90 days.
Omega Therapeutics, founded by Flagship Pioneering, is a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines. The company's OMEGA Epigenomic Programming™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth, and differentiation to cell death. Using a suite of technologies, paired with Omega's process of systematic, rational, and integrative drug design, the OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega's modular and programmable mRNA medicines, Omega Epigenomic Controllers™, target specific epigenomic loci within insulated genomic domains, EpiZips™, from amongst thousands of unique, mapped, and validated genome-wide DNA-sequences, with high specificity to durably tune single or multiple genes to treat and cure diseases through Precision Genomic Control™. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases, including alopecia.
For more information, visit omegatherapeutics.com, or follow us on Twitter and LinkedIn.
Contacts
Media contact:
Jason Braco
LifeSci Communications
646.751.4361
jbraco@lifescicomms.com
Investor contact:
Kevin Murphy
Argot Partners
212.600.1902
ArgotOmega@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/omega-therapeutics-to-participate-in-the-2022-wedbush-pacgrow-healthcare-conference-301598098.html
SOURCE Omega Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.